Similar articles for PMID: 34916246

Year	Number of Results
2009	1
2010	2
2011	1
2012	2
2013	3
2014	3
2015	5
2016	7
2017	8
2018	16
2019	22
2020	26
2021	25
2022	20
2023	23
2024	0

1

Predictors of ¹⁸F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.

Mena E, Rowe SP, Shih JH, Lindenberg L, Turkbey B, Fourquet A, Lin FI, Adler S, Eclarinal P, McKinney YL, Citrin DE, Dahut W, Wood BJ, Chang R, Levy E, Merino M, Gorin MA, Pomper MG, Pinto PA, Eary JF, Choyke PL, Pienta KJ. Mena E, et al. J Nucl Med. 2022 Aug;63(8):1184-1190. doi: 10.2967/jnumed.121.262347. Epub 2021 Dec 16. J Nucl Med. 2022. PMID: 34916246 Free PMC article.

2

¹⁸F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy.

Mena E, Lindenberg ML, Turkbey IB, Shih JH, Harmon SA, Lim I, Lin F, Adler S, Eclarinal P, McKinney YL, Citrin D, Dahut W, Wood BJ, Krishnasamy V, Chang R, Levy E, Merino M, Pinto P, Eary JF, Choyke PL. Mena E, et al. J Nucl Med. 2020 Jun;61(6):881-889. doi: 10.2967/jnumed.119.234799. Epub 2019 Nov 1. J Nucl Med. 2020. PMID: 31676732 Free PMC article.

3

Patterns of disease detection using [¹⁸F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial.

Koschel S, Taubman K, Sutherland T, Yap K, Chao M, Guerrieri M, Benson A, Starmans M, Byrne G, Ong G, Macleod C, Foo M, Wong LM, Gyomber D, Ng M. Koschel S, et al. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3712-3722. doi: 10.1007/s00259-021-05354-8. Epub 2021 Apr 14. Eur J Nucl Med Mol Imaging. 2021. PMID: 33852051 Clinical Trial.

4

Prospective Evaluation of ¹⁸F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management.

Song H, Harrison C, Duan H, Guja K, Hatami N, Franc BL, Moradi F, Aparici CM, Davidzon GA, Iagaru A. Song H, et al. J Nucl Med. 2020 Apr;61(4):546-551. doi: 10.2967/jnumed.119.231654. Epub 2019 Oct 18. J Nucl Med. 2020. PMID: 31628216 Free article. Clinical Trial.

5

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

6

Pathological predictors of ¹⁸ F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.

Perry E, Talwar A, Taubman K, Ng M, Wong LM, Sutherland TR. Perry E, et al. BJU Int. 2022 Jun;130 Suppl 1(Suppl 1):28-36. doi: 10.1111/bju.15724. BJU Int. 2022. PMID: 35768883 Free PMC article.

7

Changes in Management After ¹⁸F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes.

Ng M, Guerrieri M, Wong LM, Taubman K, Sutherland T, Benson A, Byrne G, Koschel S, Yap K, Starmans M, Ong G, Macleod C, Foo M, Chao M. Ng M, et al. J Nucl Med. 2022 Sep;63(9):1343-1348. doi: 10.2967/jnumed.121.263521. Epub 2022 Jan 20. J Nucl Med. 2022. PMID: 35058320 Free PMC article.

8

Early lesion detection with ¹⁸F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer.

Wondergem M, Jansen BHE, van der Zant FM, van der Sluis TM, Knol RJJ, van Kalmthout LWM, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN. Wondergem M, et al. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1911-1918. doi: 10.1007/s00259-019-04385-6. Epub 2019 Jun 22. Eur J Nucl Med Mol Imaging. 2019. PMID: 31230088 Free PMC article.

9

[¹⁸F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL.

Perry E, Talwar A, Taubman K, Ng M, Wong LM, Booth R, Sutherland TR. Perry E, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2038-2046. doi: 10.1007/s00259-020-05143-9. Epub 2021 Jan 5. Eur J Nucl Med Mol Imaging. 2021. PMID: 33399941

10

Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.

Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, Mottaghy FM, Behrendt FF. Verburg FA, et al. Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):397-403. doi: 10.1007/s00259-015-3240-1. Epub 2015 Nov 12. Eur J Nucl Med Mol Imaging. 2016. PMID: 26563121

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

125 results

Results by year